{"id":"W4410506512","doi":"10.1097/hep.0000000000001385","title":"Immune-mediated adverse events and overall survival with tremelimumab plus durvalumab and durvalumab monotherapy in unresectable HCC: HIMALAYA phase III randomized clinical trial","year":2025,"lang":"en","type":"article","venue":"Hepatology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"ca_institutions":"St. Michael's Hospital; University of Calgary","funders":"","keywords":"Durvalumab; Tremelimumab; Hepatocellular carcinoma; Medicine; Adverse effect; Internal medicine; Randomized controlled trial; Oncology; Clinical trial; Immune system; Immunotherapy; Gastroenterology; Nivolumab; Immunology; Cancer; Ipilimumab","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.002542732,0.0003808419,0.002398986,0.0003688548,0.0001099729,0.00001372281,0.0001298537,0.0004020201,0.0001998148],"category_scores_gemma":[0.0004393831,0.0002934039,0.0002560584,0.0003762393,0.0006472633,0.0001170056,0.00006904548,0.0004698882,0.00000407634],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001932055,"about_ca_system_score_gemma":0.0007734484,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002158644,"about_ca_topic_score_gemma":0.0008784832,"domain_scores_codex":[0.995868,0.001269398,0.00137472,0.0006996647,0.0002623905,0.0005257975],"domain_scores_gemma":[0.9975919,0.001424668,0.0003088496,0.0004366181,0.00009372244,0.0001442163],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9514833,0.0007860105,0.040094,0.00007618681,0.0009593518,0.0001515429,0.0002649887,0.000001157521,0.0006122294,0.000140462,0.0001300735,0.00530071],"study_design_scores_gemma":[0.9795768,0.002197172,0.009527954,0.0001994097,0.0003016811,0.00008103825,0.0001432345,0.005420142,0.0001198602,0.0001428512,0.002005891,0.0002839126],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9899657,0.004129024,0.0002053807,0.00133426,0.000830601,0.002752801,0.00001641077,0.0000716742,0.0006941474],"genre_scores_gemma":[0.9909432,0.006743874,0.0001798557,0.0008882384,0.00008689645,0.0002258276,0.00007236963,0.00003737884,0.000822389],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.03056604,"threshold_uncertainty_score":0.9999518,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02808413389112019,"score_gpt":0.3553463013616205,"score_spread":0.3272621674705004,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}